Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Stems Cells Successfully Transplanted onto Human Cornea

By BiotechDaily International staff writers
Posted on 30 Apr 2012
Scientists for the first time successfully cultivated human embryonic stem cells (hESCs) on damaged human corneas. The procedure may in the future lead to removal of the current dependence on donated corneas of which there continues to be a shortage.

Of the approximately 100,000 corneal transplantations carried out worldwide each year, about 500 take place in Sweden, many of which are carried out at the ophthalmology clinic at Sahlgrenska University Hospital (Mölndal, Sweden). The damaged and cloudy cornea that is turning the patient blind is replaced with a healthy, transparent one. In collaboration with scientists at the Sahlgrenska Academy of the University of Gothenburg (Sweden) and others, defective corneas obtained from the clinic were used in a study to investigate whether cells originating from hESCs could be successfully transplanted onto a partially wounded human cornea, and to examine the ability of the transplanted cells to further differentiate into corneal epithelial-like cells. It is the epithelial cells that maintain the transparency of the cornea.

The method involved in vitro transplantation of differentiated hESCs onto a human corneal button (without limbus) from which the epithelial layer was partially removed. The cells were cultured on Bowman's membrane and the culture dynamics were documented in a time-lapse system. The transplanted cells originated from a genetically engineered hESC line that expresses green fluorescent protein, which facilitated their identification. To detect differentiation into corneal epithelial-like cells, the transplanted cells were analyzed periodically for several days by immunohistochemistry using antibodies specific for relevant markers. The transplanted cells established and expanded on Bowman's membrane, forming a 1-4 cell layer surrounded by host corneal epithelial cells, and expression of a corneal marker began to appear 3 days after transplantation.

The success of these experiments represents an important step towards replacing donated corneas with corneas cultivated from stem cells. “Similar experiments have been carried out on animals, but this is the first time that stem cells have been grown on damaged human corneas. It means that we have taken the first step towards being able to use stem cells to treat damaged corneas,” said Charles Hanson, first author of the study and Associate Professor at the Sahlgrenska Academy.

“If we can establish a routine method for this, the availability of material for patients who need a new cornea will be essentially unlimited. Both the surgical procedures and the aftercare will also become much more simple,” added Ulf Stenevi, senior author of the study and Professor at the Sahlgrenska Academy.

The study was published in the journal Acta Ophthalmologica online ahead of print January 26, 2012.

Related Links:
Sahlgrenska Academy, University of Gothenburg
Sahlgrenska University Hospital


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.